AUTHOR=Tsiambas Evangelos , Chrysovergis Aristeidis , Papanikolaou Vasileios , Mastronikolis Nicholas , Ragos Vasileios , Batistatou Anna , Peschos Dimitrios , Kavantzas Nikolaos , Lazaris Andreas C. , Kyrodimos Efthimios TITLE=Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines JOURNAL=Frontiers in Molecular Biosciences VOLUME=8 YEAR=2021 URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.654866 DOI=10.3389/fmolb.2021.654866 ISSN=2296-889X ABSTRACT=
Coronavirus-related Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) initially was detected in Wuhan, Hubei, China. Since early 2021, World Health Organization (WHO) has declared Coronavirus Disease 2019 (COVID-19) a pandemic due to rapidly transformed to a globally massive catastrophic viral infection. In order to confront this emergency situation, many pharmaceutical companies focused on the design and development of efficient vaccines that are considered necessary for providing a level of normalization in totally affected human social-economical activity worldwide. A variety of vaccine types are under development, validation or even some of them have already completed these stages, initially approved as conditional marketing authorisation by Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national health authorities for commercial purposes (